Myricetin inhibits IL-1beta-induced inflammatory mediators in SW982 human synovial sarcoma cells.
Rheumatoid arthritis (RA) synovial fibroblasts produce inflammatory mediators, which destruct cartilage and bone in RA joint. The aim of this study is to investigate the effect of myricetin on inflammatory cytokine/matrix metalloproteinase (MMP) production and mitogen-activated protein kinases (MAPKs) in IL-1beta-stimulated SW982 synovial cells. Myricetin significantly decreased IL-1beta-induced production of IL-6 and MMP-1 in synovial cells. Moreover, myricetin diminished the phosphorylation of Jun NH2-terminal kinase (JNK) and p38 MAPK. These results suggest that myricetin reduces the production of MMP and IL-6 in SW982 cells by inhibiting MAPKs (JNK and p38).
Lee
Young Soon
YS
Department of Food & Nutrition, Kyung Hee University, 1 Hoegi-dong, Dongdaemun-gu, Seoul 130-701, South Korea.
Choi
Eun Mi
EM
D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D045744:Cell Line, Tumor; D004789:Enzyme Activation / Q000187:drug effects; D005347:Fibroblasts / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D005419:Flavonoids / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism; D053583:Interleukin-1beta / Q000276:immunology / Q000378:metabolism; D015850:Interleukin-6 / Q000235:genetics / Q000378:metabolism*; D020781:Matrix Metalloproteinase 1 / Q000235:genetics / Q000378:metabolism*; D013584:Sarcoma, Synovial / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D015398:Signal Transduction / Q000187:drug effects; D013583:Synovial Membrane / Q000473:pathology; D048051:p38 Mitogen-Activated Protein Kinases / Q000235:genetics / Q000378:metabolism
D005419:Flavonoids; D018836:Inflammation Mediators; D053583:Interleukin-1beta; D015850:Interleukin-6; C040015:myricetin; D048051:p38 Mitogen-Activated Protein Kinases; D020781:Matrix Metalloproteinase 1